These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

155 related articles for article (PubMed ID: 16378658)

  • 21. Multicentre randomised phase III study comparing the same dose and schedule of cisplatin plus the same schedule of vinorelbine or gemcitabine in advanced non-small cell lung cancer.
    Martoni A; Marino A; Sperandi F; Giaquinta S; Di Fabio F; Melotti B; Guaraldi M; Palomba G; Preti P; Petralia A; Artioli F; Picece V; Farris A; Mantovani L
    Eur J Cancer; 2005 Jan; 41(1):81-92. PubMed ID: 15617993
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Combination chemotherapy with gemcitabine and cisplatin in the treatment of advanced non-small cell lung cancer: preliminary results of an ongoing phase I/II study.
    Steward WP; Dunlop DJ; Cameron C; Talbot DC; Kleisbauer JP; Thomas P; Guerin JC; Perol M; Sanson C; Dabouis G
    Anticancer Drugs; 1995 Dec; 6 Suppl 6():33-7. PubMed ID: 8718423
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Phase II trial of a 2-h infusion of gemcitabine plus carboplatin as first-line chemotherapy for advanced non-small-cell lung cancer.
    Xu N; Shen P; Zhang XC; Yu LF; Bao HY; Shi GM; Huang S; Chen J; Mou HB; Fang WJ
    Cancer Chemother Pharmacol; 2007 Jan; 59(1):1-7. PubMed ID: 16614849
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Gemcitabine administered as a short infusion versus a fixed dose rate in combination with cisplatin for the treatment of patients with advanced non-small cell lung cancer.
    Pereira JR; Fein L; Del Giglio A; Blajman CR; Richardet E; Schwartsmann G; Orlando M; Hall BJ; West TM; van Kooten M
    Lung Cancer; 2007 Oct; 58(1):80-7. PubMed ID: 17588704
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Factorial phase III randomised trial of rofecoxib and prolonged constant infusion of gemcitabine in advanced non-small-cell lung cancer: the GEmcitabine-COxib in NSCLC (GECO) study.
    Gridelli C; Gallo C; Ceribelli A; Gebbia V; Gamucci T; Ciardiello F; Carozza F; Favaretto A; Daniele B; Galetta D; Barbera S; Rosetti F; Rossi A; Maione P; Cognetti F; Testa A; Di Maio M; Morabito A; Perrone F;
    Lancet Oncol; 2007 Jun; 8(6):500-12. PubMed ID: 17513173
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Gemcitabine and vinorelbine in advanced nonsmall cell lung carcinoma: a phase II study.
    Lilenbaum R; Cano R; Schwartz M; Siegel L; Lutzky J; Lewis M; Krill E; Barreras L; Davila E
    Cancer; 2000 Feb; 88(3):557-62. PubMed ID: 10649247
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Phase I study of gemcitabine given weekly as a short infusion for non-small cell lung cancer: results and possible immune system-related mechanisms.
    Levitt ML; Kassem B; Gooding WE; Miketic LM; Landreneau RJ; Ferson PF; Keenan R; Yousem SA; Lindberg CA; Trenn MR; Ponas RS; Tarasoff P; Sabatine JM; Friberg D; Whiteside TL
    Lung Cancer; 2004 Mar; 43(3):335-44. PubMed ID: 15165093
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Docetaxel/gemcitabine or cisplatin/gemcitabine followed by docetaxel in the first-line treatment of patients with metastatic non-small cell lung cancer (NSCLC): results of a multicentre randomized phase II trial.
    Binder D; Schweisfurth H; Grah C; Schäper C; Temmesfeld-Wollbrück B; Siebert G; Suttorp N; Beinert T
    Cancer Chemother Pharmacol; 2007 Jun; 60(1):143-50. PubMed ID: 17031643
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Cisplatin plus gemcitabine on days 1 and 4 every 21 days for solid tumors: result of a dose-intensity study.
    Parra HS; Cavina R; Latteri F; Campagnoli E; Morenghi E; Torri W; Brambilla G; Alloisio M; Santoro A
    Invest New Drugs; 2007 Feb; 25(1):57-62. PubMed ID: 16699975
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Gemcitabine and cisplatin treatment of advanced-stage non-small-cell lung cancer in patients given cisplatin on day 8.
    Akcali Z; Calikusu Z; Sakalli H; Ozyilkan O
    Tumori; 2008; 94(4):474-80. PubMed ID: 18822681
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The novel and effective nonplatinum, nontaxane combination of gemcitabine and vinorelbine in advanced nonsmall cell lung carcinoma: potential for decreased toxicity and combination with biological therapy.
    Herbst RS; Khuri FR; Lu C; Liu DD; Fossella FV; Glisson BS; Pisters KM; Shin DM; Papadimitrakopoulou VA; Kurie JM; Blumenschein G; Kies MS; Zinner R; Jung MS; Lu R; Lee JJ; Munden RF; Hong WK; Lee JS
    Cancer; 2002 Jul; 95(2):340-53. PubMed ID: 12124835
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A phase II study of a novel gemcitabine plus cisplatin regimen administered every three weeks for advanced non-small-cell lung cancer.
    Castellano D; Lianes P; Paz-Ares L; Hidalgo M; Guerra JA; Gómez-Martín C; Gómez H; Calzas J; Cortés-Funes H
    Ann Oncol; 1998 Apr; 9(4):457-9. PubMed ID: 9636840
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Combination of gemcitabine and cisplatin for advanced non-small cell lung cancer: a phase II study with emphasis on scheduling.
    Huisman C; Giaccone G; van Groeningen CJ; Sutedja G; Postmus PE; Smit EF
    Lung Cancer; 2001; 33(2-3):267-75. PubMed ID: 11551422
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Gemcitabine combined with cisplatin as neoadjuvant chemotherapy in stage IB-IIIA non-small cell lung cancer.
    Davidov MI; Polotzky BE; Marenich AF; Orlov SV; Lazarev AF; Skryabina LS; Pavlushkov EV; Semenchenya VA; Brichkova OY; Karaseva VV
    Anticancer Drugs; 2011 Jul; 22(6):569-75. PubMed ID: 21487288
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Phase II trial of gemcitabine and weekly cisplatin for advanced non-small cell lung cancer.
    Shepherd FA; Cormier Y; Burkes R; Evans WK; Goss G; Klimo P; Feld R; Taylor M
    Semin Oncol; 1997 Jun; 24(3 Suppl 8):S8-27-S8-30. PubMed ID: 9207313
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A phase II study of carboplatin plus gemcitabine in advanced non-small-cell lung cancer (NSCLC): a hoosier oncology group study.
    Ng EW; Sandler AB; Robinson L; Einhorn LH
    Am J Clin Oncol; 1999 Dec; 22(6):550-3. PubMed ID: 10597737
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Phase I-II trial of low-dose gemcitabine in prolonged infusion and cisplatin for advanced non-small cell lung cancer.
    Zwitter M; Kovac V; Smrdel U; Kocijancic I; Segedin B; Vrankar M
    Anticancer Drugs; 2005 Nov; 16(10):1129-34. PubMed ID: 16222156
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The efficacy and relationship between peak concentration and toxicity profile of fixed-dose-rate gemcitabine plus carboplatin in patients with advanced non-small-cell lung cancer.
    Wang L; Wu X; Huang M; Cai J; Xu N; Liu J
    Cancer Chemother Pharmacol; 2007 Jul; 60(2):211-8. PubMed ID: 17124596
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Randomized phase II study comparing weekly docetaxel-cisplatin vs. gemcitabine-cisplatin in elderly or poor performance status patients with advanced non-small cell lung cancer.
    Jang J; Kim HK; Cho BC; Lee KH; Yun HJ; Woo IS; Song HS; Ryoo HM; Kim CH; Sun DS; Shin JW
    Cancer Chemother Pharmacol; 2017 May; 79(5):873-880. PubMed ID: 28341958
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A phase II trial of vinorelbine plus gemcitabine in previously untreated inoperable (stage IIIb/IV) non-small-cell lung cancer patients aged 80 or older.
    Chen YM; Perng RP; Chen MC; Tsai CM; Ming-Liu J; Whang-Peng J
    Lung Cancer; 2003 May; 40(2):221-6. PubMed ID: 12711125
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.